M&A: RENOVARO INC.

Form Type: 8-K

Filing Date: 2025-01-07

Corporate Action: Acquisition

Type: New

Accession Number: 000173112225000037

Comments: On January 6, 2025, Renovaro Inc. announced its entry into a binding letter of intent to acquire Predictive Oncology Inc. The acquisition will be executed through the merger of Predictive Oncology into Renovaro in exchange for a new series of preferred stock. Shareholders of Predictive Oncology will receive preferred stock on a 1:1 basis for their common stock. This preferred stock is redeemable at $3.00 per share after 18 months and can be converted to registered common stock of Renovaro at a 1:1 ratio once certain trading conditions are met. Renovaro must raise at least $15 million and secure shareholder approval from Predictive Oncology for the merger to proceed. Additionally, they have agreed to purchase up to 2.33 million shares of Predictive Oncology common stock at $1.07 each if certain warrants are not exercised by January 15, 2025. The merger documentation is expected to be finalized by February 28, 2025, with conditions tied to capital raised for Predictive Oncology.

Document Link: View Document